Suppository treatment in ulcerative proctitis-Reference-Cited by-同舟云学术

Suppository treatment in ulcerative proctitis

Published:2021-01 Issue: Volume:19 Page:205873922110151
ISSN:2058-7392
Container-title:European Journal of Inflammation
language:en
Short-container-title:Eur J Inflamm

Author:

Si Yingjie¹,Shao LanJun²,Gao Shanqing³,Wen Hongzhu¹^ORCID

Affiliation:

1. Department of Gastroenterology, Longhua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

2. Department of Internal Medicine, Qingpu District Traditional Chinese Medicine Hospital, Shanghai, China

3. Department of Internal Medicine, Fengxian District Traditional Chinese Medicine Hospital, Shanghai, China

Abstract

Ulcerative proctitis (UP) is a common form of ulcerative colitis (UC), the number of patients with UP is increasing. Suppository treatment containing mesalamine is usually the first-line choice for mild to moderate UP, here, we review the publications on mesalamine suppository in UP, to better understand its dosage, duration of therapy and adverse events in both induction and maintenance phases. We also review articles on budesonide, beclomethasone, tacrolimus, herbal medicine and acetarsol suppositories in UP, to present therapeutic strategies for patients with UP refractory to mesalamine suppository.

Funder

Research Project of Longhua Hospital in 2016

Scholar Project of Longhua hospital

National Natural Science Foundation of China

Publisher

SAGE Publications

Link

http://journals.sagepub.com/doi/pdf/10.1177/20587392211015108

Reference49 articles.

1. Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

2. Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study

3. ACG Clinical Guideline: Ulcerative Colitis in Adults

4. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis